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INTRODUCTION: Methotrexate, a folate antagonist, is a mainstay treatment for childhood acute lymphoblastic leukemia. It is 
also widely used in a low dose formulation to treat patients with rheumatoid arthritis. In rats, methotrexate is known to induce 
micronuclei formation, leading to genetic damage, while vitamin A is known to protect against such methotrexate-induced genetic 
damage. Leucovorin (folinic acid) is generally administered with methotrexate to decrease methotrexate-induced toxicity. 
OBJECTIVES: We aimed to determine whether vitamin A and leucovorin differed in their capacity to prevent formation of 
methotrexate-induced micronuclei in rat bone marrow erythrocytes. The present study also aimed to evaluate the effect of combined 
treatment with vitamin A and leucovorin on the formation of methotrexate-induced micronuclei.
METHODS: Male and female Wistar rats (n=8) were injected with 20 mg/kg methotrexate (single i.p. dose). The control group 
received an equal volume of distilled water. The third and fourth groups of rats received vitamin A (5000 IU daily dose for 4 suc-
cessive days) and leucovorin (0.5 mg/kg i.p. dose for 4 successive days), respectively. The fifth and sixth groups of rats received 
a combination of vitamin A and a single dose of methotrexate and a combination of leucovorin and methotrexate, respectively. 
The last group of rats received a combination of leucovorin, vitamin A and single dose of methotrexate. Samples were collected at 
24 hours after the last dose of the treatment into 5% bovine albumin. Smears were obtained and stained with May-Grunwald and 
Giemsa. One thousand polychromatic erythrocytes were counted per animal for the presence of micronuclei and the percentage of 
polychromatic erythrocyte was determined.
RESULTS: Comparison of methotrexate-treated rats with the control group showed a significant increase in the percentage of cells 
with micronuclei and a significant decrease polychromatic erythrocyte percentage. Combined methotrexate and vitamin A therapy 
and combined methotrexate and leucovorin therapy led to significant decreases in the micronuclei percentage and an increase in 
polychromatic erythrocyte percentage when compared to rats treated with methotrexate alone. Leucovorin was found to be more 
effective than vitamin A against the formation of methotrexate-induced micronuclei.
CONCLUSIONS: Both vitamin A and leucovorin provided significant protection against genetic damage induced by methotrexate.
KEYWORDS: Micronuclei; Rat bone marrow erythrocytes; Methotrexate; Vitamin A; Leucovorin.
INTRODUCTION
Methotrexate, an inhibitor of dihydrofolate reductase, 
is known to induce micronuclei formation upon multiple 
doses.1 Methotrexate is a mainstay treatment for childhood 
acute lymphoblastic leukemia with meningeal infiltration 
and also for many other forms of carcinoma. Methotrexate 
has also become an important therapeutic alternative for 
the treatment of severe psoriasis2 as methotrexate has anti-
inflammatory properties. More specifically, it reduces 
lymphocyte proliferation, rheumatoid factor production 
and leukocyte interactions. It is used intermittently at a 
low dosage to induce remission of refractory rheumatoid 822
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arthritis.3 Methotrexate is also used in the management of 
ectopic pregnancy.4,5 Methotrexate restricts the synthesis of 
thymidylate and purine nucleotides by inhibiting dihydrofolate 
reductase and, to a lesser extent, thymidylate synthatase. In 
cells treated with methotrexate, a progressive accumulation 
of strand breaks in mature DNA (post-replicated DNA) was 
detected by Li and Kaminskas.6 They postulated that the 
strand brake arose from spontaneous and normally repaired 
DNA lesions that were not repaired due to a shortage of dTTP 
and purine nucleotides. The cytogenetic effect of methotrexate 
has been studied in mouse tumors,7 cultured potorous cells8 
and human cells in vivo.9 Methotrexate was found to be a 
clastogenic agent in tumor cells and in cultured mammalian 
cells. A collaborative study10 on various chemicals for 
micronuclei formation revealed that only methotrexate had a 
positive response in a single dose. 
Many reports11,12 suggest that vitamin A protects against 
micronuclei induction. In an earlier study,13 rats treated 
with a combination of methotrexate and vitamin A had a 
significantly reduced frequency of micronuclei formation 
when compared to methotrexate (20mg/kg)-treated rats. 
Leucovorin is a form of folic acid. Folic acid is a 
naturally occurring substance that is important for the 
formation of red and white blood cells. Folic acid is present 
in many foods, such as beans, peas, oranges, spinach. 
Leucovorin is used to reduce the side effects of large 
doses of medications, such as methotrexate (Rheumatrex), 
pyrimethamine (Daraprim), trimethoprim (Trimpex, 
Proloprim), that may reduce the effects of folic acid in 
the body. In the present study, we planned to compare the 
efficacy of vitamin A with that of leucovorin with respect 
to their ability to inhibit formation of methotrexate-induced 
micronuclei. We also planned to evaluate the effects of drug 
combinations on methotrexate-induced micronuclei in the 
bone marrow of rats.
MATERIALS & METHODS
Animals: Male and female adult Wistar rats weighing 
approximately 150-170 (158.5 ± 6.34) g were used in this 
study. Animals were selected on the basis of adequate body 
weight gain and the lack of any clinical signs of disease 
or injury. All animals were identified by tail marking with 
indelible ink, which lasted for the duration of the study. The 
animals were individually weighed and randomly assigned 
to one of seven groups so that there were no statistically 
significant differences among group body weight means. 
Each group consisted of eight animals (four males and four 
females). Animals were maintained under controlled light 
(10h light: 14h dark), temperature (22±3°C), and humidity 
(approximately 50±10%) conditions in an air-conditioned 
animal house. All rats were maintained on standard rat 
food and water ad libitum. The experimental procedure was 
approved by the institutional ethics committee. Breeding 
and maintenance of the animals were in accordance with 
the guidelines of the Government of India for the use of 
laboratory animals. 
Animal groups
Group 1: Rats were given an equivalent volume of 
distilled water.
Group 2: Rats received 20 mg/kg body weight dose of 
methotrexate (single i.p. dose)
Group 3: Rats received vitamin A (5000 IU for four 
successive days)
Group 4: Rats received leucovorin (0.5 mg/kg for four 
successive days)
Group 5: Rats received methotrexate (20 mg/kg, single, 
i.p. dose) and vitamin A (5000 IU for four successive days 
before the administration of methotrexate)
Group 6: Rats received methotrexate (20 mg/kg, single 
i.p. dose) and leucovorin (0.5 mg/kg for four successive days 
before the administration of methotrexate) 
Group 7: Rats received methotrexate (20 mg/kg, single 
i.p. dose) along with vitamin A (5000 IU for four successive 
days) and leucovorin (0.5 mg/kg for four successive days) 
before the administration of methotrexate.
Chemicals
Methotrexate, vitamin A and leucovorin (calcium 
leucovorin) were obtained from Biochem Pharmaceutical 
Industries (Ahmedabad, India). Bovine albumin (Sigma 
grade, 96-99% B No.140), May-Gruenwald powder and 
Giemsa powder were obtained from Romoli Co., (Mumbai). 
All other chemicals and reagents were of HPLC or analytical 
grade (Sigma, St. Louis, Mo.).
Micronuclei test
In the present study, Schmid’s14 standard procedure was 
followed with slight modifications. Instead of foetal calf 
serum, 5% bovine albumin was used as suspending medium 
to collect the bone marrow15. The rats were sacrificed 24h after 
the last methotrexate treatment, femurs were trimmed, and 
a blunt needle was pushed to pierce the marrow cavity. The 
marrow was flushed through a syringe by 5% bovine albumin 
to obtain a fine suspension. The suspension was centrifuged at 
1000 rpm for 8 to 10 minutes. The supernatant was discarded 
and half of a drop of fresh suspending medium was added 
and mixed thoroughly by a Pasteur pipette. A small drop of 823
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suspension was placed on one end of the slide and a smear 
was prepared (3-4 slides/animal). Slides were cooled and air 
dried overnight, fixed by methanol for 5 minutes, dried and 
stained with May-Grunwald and then with a combination of 
May-Grunwald and phosphate buffer, pH 6.8, for the proper 
color differentiation of polychromatic erythrocytes (PCEs) 
and normochromatic erythrocytes (NCEs). Finally, slides 
were stained with Geimsa and phosphate buffer, pH 6.8, 
for micronuclei staining. After washing with distilled water 
and phosphate buffer, slides were dried and mounted. One 
thousand PCEs were screened per animal and micronucleated 
PCEs (MNPCEs) were quantified. Consequently, identified 
NCEs and micronucleated NCEs (MNNCEs) were quantified. 
The percentages of MNPCE and PCE were calculated for 
each animal.
Statistical analysis
The data are expressed as mean ± SD. The significance 
of differences among the groups were assessed using an 
one way analysis of variance (ANOVA) test followed by 
Bonferroni’s multiple comparison test. P values < 0.05 are 
considered as significant. Differences in the data for the male 
and female groups were assessed by the Mann-Whitney 
unpaired t test. 
RESULTS
Sex-related differences were not observed with respect 
to either micronuclei induction or PCE%; therefore, data 
from males and females were collapsed into one group. 
Methotrexate induced a significantly greater (p<0.001) 
number of micronuclei when compared to the control 
(group 1), vitamin A-treated (group 3), or leucovorin-treated 
groups (group 4). There was not a significant difference 
(p>0.05) between control and vitamin A (group 3)-treated 
or leucovorin (group 4)-treated rats. The micronuclei 
percentage was significantly reduced (p<0.001) in the 
combined methotrexate and vitamin A (group 5) treatment 
group as well as in the combined methotrexate and 
leucovorin (group 6) treatment group when compared to the 
methotrexate (group 2)-treated rats. Combined treatment 
with vitamin A and leucovorin with methotrexate (group 
7) did not show any significant difference (p>0.05) when 
compared to the combined methotrexate and vitamin A 
(group 5) or methotrexate and leucovorin (group 6) treatment 
groups. These results indicate that treatment with vitamin A 
and leucovorin had the same effect as treatment with vitamin 
A or leucovorin alone. The percentage of cells with induced 
micronuclei was marginally significantly (p<0.05) different 
for the methotrexate and vitamin (group 5) treatment group 
relative to the methotrexate and leucovorin (group 6) 
treatment group. This result indicates that leucovorin exerts a 
greater protective effect than vitamin A against methotrexate-
induced micronuclei formation (Figure 1). 
The PCE% differed significantly (p<0.01) between the 
methotrexate-treated (group 2) and control (group 1) groups 
of rats. The PCE% was significantly increased (p<0.05) in 
the group treated with methotrexate and vitamin A (group 
5) as well as that treated with methotrexate and leucovorin 
(group 6) when compared with methotrexate-treated rats 
(group 2) (Figure 2). The PCE% did not differ between the 
groups treated with methotrexate and vitamin A (group 5) 
and methotrexate and leucovorin (group 6).
Figure 1 - The percentage of micronuclei-induction in various gropus of rats. Error bar indicates ± SE (n=8), Anova significance, F=53.145824
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DISCUSSION
Methotrexate is widely used, in low doses, for the 
treatment of psoriasis,16 autoimmune diseases, inflammatory 
bowel diseases, asthma,17-20 inflammatory myopathy,21 and 
panuveitis.22 The clinical utility of methotrexate must be 
checked against its potential side effects.23 
People with low and high micronuclei yields show 
low and high frequencies of chromosome aberration, 
respectively.24 Hence, the micronuclei assay is often used 
to detect the frequency of chromosomal aberrations. As a 
number of genetic diseases are characterized by instable 
chromosomes or by mal-distribution of chromosomes, it 
is not surprising that also micronucleus frequencies are 
higher in patients in some of the genetic diseases. Drug-
induced chromosomal aberrations or the mal distribution 
of chromosomes can lead to the development of genetic 
disease.25 These chromosomal changes may also lead to 
the development of tumors.26 According to this hypothesis, 
a patient with a high micronuclei score is prone to 
chromosome breakage which may lead to tumor formation. 
Stich et al.27 presented evidence which indicated that 
micronuclei may serve as predictors of carcinogenic risk. 
This group demonstrated that, after exposure to certain 
chemicals, tissues that are at elevated risk for cancer show a 
markedly enhanced number of micronuclei.
In the present study, methotrexate-treated rats had 
a significantly increased number of micronuclei when 
compared to a control group of rats. Methotrexate penetrates 
bone marrow cells and binds to the dihydrofolate reductase 
enzyme, thereby completely inhibiting its activity. 
Continuous inhibition of DHFR may cause an imbalance in 
the deoxynucleotide pools due to shortages in thymidylate 
and purine nucleotides, which may result in the formation of 
DNA lesions.6 In addition, complete inhibition of DHFR may 
severely suppress the generation of PCEs from erythroblasts 
in the bone marrow. 
Rats treated with vitamin A and methotrexate had a 
significantly reduced number of micronuclei when compared 
to rats treated with methotrexate alone, demonstrating 
the protective effect of vitamin A. Rats treated with 
vitamin A alone did not present a significant difference 
in spontaneous micronuclei formation when compared to 
control rats, which received distilled water. The PCE% was 
increased in rats treated with vitamin A and methotrexate 
when compared to rats treated with methotrexate alone. 
Hence, our study confirms that vitamin A minimizes the 
genotoxic and cytotoxic effects of methotrexate. The 
protective effect of vitamin A against genotoxicity and 
cancer chemoprevention has been studied by many groups. 
Slamenova et al.11 observed that dietary intake of vitamin A 
reduced micronuclei induction in rat hepatocytes challenged 
with various carcinogens. Similar results were reported 
by Alaovi-Jamali et al.28 Protective effects of vitamin A 
against micronuclei induction in buccal mucosa of betel nut/
tobacco chewers were also reported.29,30 Numerous in vitro 
experiments have been performed in order to verify the true 
role played by beta-carotene, a precursor of vitamin A on 
cell proliferation and differentiation; until now, findings have 
been very encouraging, uniformly showing that beta-carotene 
can affect carcinogenesis, particularly in early stages, 
through an antigenotoxic action. Antioxidant functions, 
immunomodulatory effects and control of intercellular 
messages via gap junctions are possible action mechanisms 
of the ability of beta-carotene to block the carcinogenetic 
process.31 
Figure 2 - The percentage of polychromatic erythrocyte in various gropus of rats. Error bar indicates ± SE (n=8), Anova significance, F=8.001825
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The results of the present study clearly demonstrate that 
leucovorin has a protective effect against methotrexate-
induced micronuclei formation in rat bone marrow. The 
PCE% was enhanced in rats treated with leucovorin 
and methotrexate when compared to rats treated with 
methotrexate alone. Interestingly, leucovorin-treated 
rats showed a reduced number of micronuclei following 
methotrexate treatment when compared to vitamin A-treated 
rats. Thus, our study clearly demonstrates that leucovorin is 
more effective than vitamin A against methotrexate-induced 
micronuclei in rat bone marrow. Our study also indicates 
that the combination of vitamin A and leucovorin had almost 
the same effect as vitamin A or leucovorin alone against 
methotrexate-induced micronuclei formation. Folinic acid 
(leucovorin) is a 5-formyl derivative of tetrahydrofolic 
acid. It is readily converted to other reduced folic acid 
derivatives (e.g. tetrahydrofolate), and thus has vitamin 
activity which is equivalent to folic acid. However, since it 
does not require the action of dihydrofolate reductase for 
its conversion, its function as a vitamin is unaffected by 
inhibition of this enzyme by drugs such as methotrexate. 
Folinic acid, therefore, allows for purine/pyrimidine 
synthesis to occur in the presence of dihydrofolate reductase 
inhibition, such that some normal DNA replication and 
RNA transcription processes can proceed. Folinic acid is 
administered at the appropriate time following methotrexate 
as part of a complete chemotherapeutic plan, so that it 
may “rescue” bone marrow and gastrointestinal mucosa 
cells from methotrexate. Shahin et al.32 demonstrated the 
protective effects of leucovorin against methotrexate-induced 
genotoxicity in humans as well as animal models. Similar 
results were also reported by Chennakeshava et al.33
The results of the present study are in accord with 
previous studies that have shown amelioration of the 
genotoxic effects of methotrexate by both vitamin A and 
leucovorin in rats. In addition, the present study claims 
that leucovorin is more effective at minimizing micronuclei 
induction in comparison to vitamin A. Interestingly, 
combined treatment with both vitamin A and leucovorin 
was not significantly different from treatment with either 
vitamin A or leucovorin alone with regard to protection from 
methotrexate-induced micronuceli formation.
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